On Thursday, QSM Asset Administration revealed a serious acquisition of Pfizer Inc. (PFE 0.16%)added an estimated $6.8 million value of shares within the third quarter.
what occurred
QSM Asset Administration elevated its stake in Pfizer, including 276,899 shares within the third quarter of 2025, based on a Securities and Change Fee submitting launched Thursday. The estimated acquisition worth was roughly $6.8 million for the quarter ended September 30, primarily based on common inventory costs for the interval. This brings the corporate’s whole holdings of Pfizer inventory to 460,743 shares, value $11.3 million.
What else it’s good to know
QSM’s Pfizer place presently represents 8.1% of the fund’s 13F property below administration.
High holding shares after software:
NYSE:ZBH: $12.9 million (9.2% of property below administration) NASDAQ:INTC: $12.2 million (8.7% of property below administration) NASDAQ:VTRS: $11.6 million (8.3% of property below administration) NYSE:RIO: $11.5 million (8.2% of property below administration) NYSE:PFE: $11.3 million (8.1% of property below administration)
As of Thursday morning, Pfizer inventory was priced at $24.52, down 17% over the previous 12 months and lagging the S&P 500, which has risen 15% over the identical interval.
Firm Profile
Firm snapshot
Pfizer provides a various portfolio of biopharmaceutical merchandise, together with medicines and vaccines for cardiovascular, infectious, immunological and uncommon ailments. This huge pharmaceutical firm generates its income primarily by way of the invention, growth, manufacturing, and worldwide distribution of branded medicines and vaccines. We serve wholesalers, retailers, hospitals, clinics, authorities companies, pharmacies, and personal companies. Supplier’s Workplace, Facilities for Illness Management and Prevention.
Pfizer is a worldwide chief within the biopharmaceutical business with a broad portfolio of modern medicines and vaccines. The corporate leverages its analysis and growth capabilities, strategic alliances and international distribution community to keep up its aggressive edge within the healthcare sector.
silly take
QSM Asset Administration added $6.8 million to Pfizer (NYSE:PFE) inventory, additional deepening its publicity to the high-dividend, undervalued healthcare inventory. This can be a transfer in step with a value-oriented funding technique geared toward producing steady returns over a five-year cycle. Pfizer, one of many firm’s prime 5 holdings, accounts for 8.1% of the portfolio, together with corporations resembling Zimmer Biomet and Intel, reflecting its tilt towards established capital-producing international leaders.
Pfizer’s most up-to-date quarter confirmed indicators of stabilization after pandemic-era volatility. The corporate reported income of $14.7 billion, a rise of 10% 12 months over 12 months. Administration reaffirmed its full-year earnings outlook and revised down its adjusted earnings per share steerage by $0.10 to roughly $3 per share. The transfer additionally comes weeks after the corporate introduced a landmark drug pricing settlement with President Donald Trump.
For long-term traders, QSM’s conviction highlights the potential upside to Pfizer’s depressed valuation and seven% dividend yield. With a powerful steadiness sheet, expanded pharmaceutical portfolio, and renewed deal with effectivity, Pfizer provides a mix of revenue and rebound potential that matches QSM’s long-term, value-driven funding thesis.
Glossary
Property Below Administration (AUM): The overall market worth of investments managed by a fund or funding firm.
13F Reportable Property: Securities (often U.S.-listed shares and sure choices) that funding managers should disclose of their quarterly SEC Kind 13F filings.
Place: The quantity of a specific safety or asset owned by an investor or fund.
Stake: The possession curiosity or stake held by an investor or fund in an organization.
Dividend yield: The annual dividend divided by the inventory value, expressed as a proportion.
Monitoring 12 Months (TTM): The 12-month interval ending with the newest quarterly report.
Biopharmaceuticals: Pertains to medication and coverings developed utilizing organic sources and biotechnology.
Wholesaler: An organization that purchases merchandise in bulk from producers on the market to retailers and different companies.
Strategic collaboration: A partnership between corporations to realize a standard enterprise aim, typically in analysis, growth, or gross sales.
Jonathan Ponciano has no place in any shares talked about. The Motley Idiot has a place in and recommends Intel and Pfizer. The Motley Idiot recommends the next choices: Brief $21 placed on Intel in November 2025. The Motley Idiot has a disclosure coverage.
